Tesla Inc. (TSLA) is said to have been given a green light by health officials to resume production at its main Fremont auto plant ending a stand-off between the electric automaker and Alameda County.Tesla informed employees it received approval to resume operations at its factory after Alameda County’s interim health officer had approved its Fremont work plan and safety measures, according to an email seen by Bloomberg.“We have local support to get back to full production at the factory starting this upcoming week,” Laurie Shelby, Tesla’s vice president for environmental, health, and safety told employees.The Alameda decision comes after Tesla’s CEO Elon Musk last week had restarted production defying Covid-19 health orders currently in place throughout Alameda County. Furthermore, Musk filed a lawsuit against the County claiming its lockdown orders have prevented the electric automaker from resuming operations at its California plant planned for earlier this month.The outspoken billionaire also threatened...
* Benzinga has examined the prospects for many investor favorite stocks over the past week. * Bullish calls included video streaming and aerospace leaders. * Bearish calls included cruise line operators and a restaurant chain.As Congress debated reopening the economy and the Federal Reserve warned that a recovery would be slow, word came of the reopening of theme parks, auto plants, tech giants and even trading floors. The major U.S. indexes ended last week in the red, led by about a 2.5% retreat in the Dow Jones industrials.As usual, Benzinga continues to examine the prospects for many of the stocks most popular with investors. Here are some of this past week's most bullish and bearish posts that are worth another look.Bulls Despite near-term volatility, Netflix Inc (NASDAQ: NFLX) is still winning buyers. So says Elizabeth Balboa's "3 Reason To Buy Netflix Stock Right Now, According To Jefferies."In "Here's How Large Boeing...
In a news-heavy week, we witnessed big earnings releases, with Aurora Cannabis Inc (NYSE: ACB) (TSE: ACB) getting the most attention.The Edmonton, Canada-based company reported a 35% sequential sales increase for the third quarter, far exceeding analyst expectations. Net revenue came in at $78.4 million, excluding provisions of $2.9 million. That's an increase of 18% over the prior quarter.While its EBITDA loss was about $10 million worse than consensus forecasted, international medical sales and Canadian recreational sales beat estimates, and gross margins expanded to 42.2%."This was clearly a case of the patient being presumed dead, when indeed it's not," Alan Brochstein, founder of 420 Investor and New Cannabis Ventures, told Benzinga.Following the release, analysts at Cantor Fitzgerald reiterated an Overweight rating and CA$22 price target, while Piper Sandler trimmed its target from CA$12 to CA$10. Brochstein expects the price to strike about CA$15.On the other hand, Tilray Inc (NASDAQ: TLRY) announced...
There's a growing realization that the COVID-19 crisis has unleashed an era of activist government that’s likely to remain a central feature of economic policy for years to come. ...
Locomation will test at the Transportation Research Center to advance its autonomous truck-platooning platforms alongside TRC’s research and development team. ...
